Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

161 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Prognostic factors in patients treated with second-line chemotherapy for advanced gastric cancer: results from the randomized prospective phase III FFCD-0307 trial.
Touchefeu Y, Guimbaud R, Louvet C, Dahan L, Samalin E, Barbier E, Le Malicot K, Cohen R, Gornet JM, Aparicio T, Nguyen S, Azzedine A, Etienne PL, Phelip JM, Hammel P, Chapelle N, Sefrioui D, Mineur L, Lepage C, Bouche O. Touchefeu Y, et al. Among authors: dahan l. Gastric Cancer. 2019 May;22(3):577-586. doi: 10.1007/s10120-018-0885-z. Epub 2018 Oct 11. Gastric Cancer. 2019. PMID: 30311042 Clinical Trial.
Maintenance treatment with fluoropyrimidine plus bevacizumab versus fluoropyrimidine alone after induction chemotherapy for metastatic colorectal cancer: The BEVAMAINT - PRODIGE 71 - (FFCD 1710) phase III study.
Manfredi S, Turpin A, Malka D, Barbier E, Laurent-Puig P, Zaanan A, Dahan L, Lièvre A, Phelip JM, Michel P, Hautefeuille V, Legoux JL, Lepage C, Tougeron D, Aparicio T. Manfredi S, et al. Among authors: dahan l. Dig Liver Dis. 2020 Oct;52(10):1143-1147. doi: 10.1016/j.dld.2020.06.034. Epub 2020 Jul 31. Dig Liver Dis. 2020. PMID: 32747302
Continuation versus discontinuation of first-line chemotherapy in patients with metastatic squamous cell oesophageal cancer: A randomised phase II trial (E-DIS).
Adenis A, Bennouna J, Etienne PL, Bogart E, Francois E, Galais MP, Ben Abdelghani M, Michel P, Metges JP, Dahan L, Conroy T, Ghiringhelli F, Drouillard A, El Hajbi F, Samalin E, Hiret S, Delaine-Clisant S, Mariette C, Penel N, Piessen G, Le Deley MC. Adenis A, et al. Among authors: dahan l. Eur J Cancer. 2019 Apr;111:12-20. doi: 10.1016/j.ejca.2019.01.016. Epub 2019 Feb 22. Eur J Cancer. 2019. PMID: 30798084 Clinical Trial.
Multicentre phase II trial of capecitabine plus oxaliplatin (XELOX) in patients with advanced hepatocellular carcinoma: FFCD 03-03 trial.
Boige V, Raoul JL, Pignon JP, Bouché O, Blanc JF, Dahan L, Jouve JL, Dupouy N, Ducreux M; Fédération Francophone de Cancérologie Digestive. Boige V, et al. Among authors: dahan l. Br J Cancer. 2007 Oct 8;97(7):862-7. doi: 10.1038/sj.bjc.6603956. Epub 2007 Sep 18. Br J Cancer. 2007. PMID: 17876335 Free PMC article. Clinical Trial.
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort.
Walter T, Tougeron D, Baudin E, Le Malicot K, Lecomte T, Malka D, Hentic O, Manfredi S, Bonnet I, Guimbaud R, Coriat R, Lepère C, Desauw C, Thirot-Bidault A, Dahan L, Roquin G, Aparicio T, Legoux JL, Lombard-Bohas C, Scoazec JY, Lepage C, Cadiot G; CEPD investigators. Walter T, et al. Among authors: dahan l. Eur J Cancer. 2017 Jul;79:158-165. doi: 10.1016/j.ejca.2017.04.009. Epub 2017 May 11. Eur J Cancer. 2017. PMID: 28501762
Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial.
Michel P, Adenis A, Di Fiore F, Boucher E, Galais MP, Dahan L, Mirabel X, Hamidou H, Raoul JL, Jacob JH, Hellot MF, Prod'homme S, Paillot B. Michel P, et al. Among authors: dahan l. Br J Cancer. 2006 Sep 18;95(6):705-9. doi: 10.1038/sj.bjc.6603328. Br J Cancer. 2006. PMID: 16967056 Free PMC article. Clinical Trial.
BAYPAN study: a double-blind phase III randomized trial comparing gemcitabine plus sorafenib and gemcitabine plus placebo in patients with advanced pancreatic cancer.
Gonçalves A, Gilabert M, François E, Dahan L, Perrier H, Lamy R, Re D, Largillier R, Gasmi M, Tchiknavorian X, Esterni B, Genre D, Moureau-Zabotto L, Giovannini M, Seitz JF, Delpero JR, Turrini O, Viens P, Raoul JL. Gonçalves A, et al. Among authors: dahan l. Ann Oncol. 2012 Nov;23(11):2799-2805. doi: 10.1093/annonc/mds135. Epub 2012 Jul 5. Ann Oncol. 2012. PMID: 22771827 Free article. Clinical Trial.
A transcriptomic signature to predict adjuvant gemcitabine sensitivity in pancreatic adenocarcinoma.
Nicolle R, Gayet O, Duconseil P, Vanbrugghe C, Roques J, Bigonnet M, Blum Y, Elarouci N, Armenoult L, Ayadi M, de Reyniès A, Puleo F, Augustin J, Emile JF, Svrcek M, Arsenijevic T, Hammel P, Giovannini M, Grandval P, Dahan L, Moutardier V, Gilabert M, Van Laethem JL, Bachet JB, Cros J, Iovanna J, Dusetti NJ. Nicolle R, et al. Among authors: dahan l. Ann Oncol. 2021 Feb;32(2):250-260. doi: 10.1016/j.annonc.2020.10.601. Epub 2020 Nov 12. Ann Oncol. 2021. PMID: 33188873 Free article.
A phase II study of retifanlimab (INCMGA00012) in patients with squamous carcinoma of the anal canal who have progressed following platinum-based chemotherapy (POD1UM-202).
Rao S, Anandappa G, Capdevila J, Dahan L, Evesque L, Kim S, Saunders MP, Gilbert DC, Jensen LH, Samalin E, Spindler KL, Tamberi S, Demols A, Guren MG, Arnold D, Fakih M, Kayyal T, Cornfeld M, Tian C, Catlett M, Smith M, Spano JP. Rao S, et al. Among authors: dahan l. ESMO Open. 2022 Aug;7(4):100529. doi: 10.1016/j.esmoop.2022.100529. Epub 2022 Jul 8. ESMO Open. 2022. PMID: 35816951 Free PMC article. Clinical Trial.
161 results